| ￥3300 | |
| Z05750-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | PGLYRP1 hFc Chimera, Human captured on CM5 Chip via Protein A can bind Human TREM1, His Tag in SPR assay (Biacore T200). Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 46.2 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 55-60 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of PGLYRP1 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC. »
PGLYRP1 hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
PGLYRP1 hFc Chimera, Human, hFc Tag captured on CM5 Chip via Protein A can bind Human TREM1, His Tag with an affinity constant of 17.39 µM as determined in SPR assay (Biacore T200). »
| Target Background | Innate immunity protein Tag7 (PGRP-S, PGLYRP1) can interact with the TNFα receptor, TNFR1, and block the transduction of apoptotic signals through this receptor. A complex formed between the Tag7 protein and the major heat shock protein Hsp70 can activate TNFR1 receptor and induce tumor cell death via either apoptotic or necroptotic pathway. |
| Synonyms | PGRP-S; PGLYRP1; PGLYRP; PGRP; TNFSF3L; PGRP-SMGC126894; PGRPSMGC126896; TAG7; Tasg7 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
